BGI didn’t infringe one Illumina patent, fails to invalidate another

The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MedTech

Abbott fends off Chinese rival’s patent challenge at UPC

18 August 2026 The European court has backed Abbott in a dispute over glucose-monitoring technology, while offering guidance on a key added-matter issue.

MedTech

Invisalign maker secures first China win against clear aligner rival

13 August 2026 Clear aligner rivals are fighting over orthodontic technology across several major markets and the latest development in China has raised the stakes.

MedTech

The UPC plugs another gap in its procedural rulebook

7 August 2026 A new UPC Court of Appeal ruling closes an important procedural gap, with significant implications for how in-house teams structure validity defences, manage litigation costs and prepare for appeals, says Florian Laus of Simmons & Simmons.

More features

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

10x Genomics dealt major blow in sequencing fight

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

Abbott fends off Chinese rival’s patent challenge at UPC

Former head of litigation at Nokia returns to Bird & Bird

Former USPTO acting director takes the helm at C4IP

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

BGI didn’t infringe one Illumina patent, fails to invalidate another

More on this story

Editor's picks

Editor's picks

More features